Polymeric IgA and IgM Therapeutics for C. difficile Toxin Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile associated diseases, such as colitis and antibiotic-associated diarrhea, often result in relapses due to disruption of intestinal flora and require high doses of monomeric immunoglobulins that are susceptible to gastrointestinal degradation, making them costly and ineffective.
Innovation Solution
Development of antigen-specific dimeric secretory IgA and pentameric secretory IgM therapeutics, combined with a recombinant secretory component, which are resistant to gastrointestinal degradation and administered in forms like capsules, tablets, or suppositories, optionally with enteric coating or microencapsulation, to provide effective treatment with lower dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monomeric immunoglobulins are administered to treat C. difficile associated diseases, then therapeutic effect is achieved, but gastrointestinal degradation occurs leading to high dosing requirements and increased cost
Solution Approach 1:
The patent changes the structural parameter of immunoglobulins from monomeric to polymeric forms (dimeric IgA and pentameric IgM). This structural modification increases resistance to gastrointestinal degradation while maintaining antigen-binding capability, thereby reducing dosing requirements and treatment cost.
Solution Approach 2:
The patent creates composite immunoglobulin structures by combining multiple immunoglobulin units (dimers of IgA, pentamers of IgM) with secretory components. These composite polymeric structures provide enhanced stability in the gastrointestinal environment compared to monomeric immunoglobulins.
2Reliability
If high doses of monomeric immunoglobulins are administered to overcome gastrointestinal degradation, then therapeutic effect is maintained, but treatment cost increases significantly
Solution Approach 1:
By changing the molecular weight and polymeric state of immunoglobulins from monomeric to dimeric/pentameric forms, the patent increases resistance to proteolytic degradation in the gastrointestinal tract. This allows lower dosing amounts to achieve the same therapeutic effect.
3Reliability
If antibiotics are used to treat C. difficile associated diseases, then bacterial infection is eliminated, but intestinal flora disruption occurs leading to relapses
Solution Approach 1:
The patent converts the harmful effect of antibiotic-induced flora disruption into a beneficial approach by using polymeric immunoglobulins that specifically target C. difficile toxins without affecting commensal bacteria. This selective neutralization approach maintains intestinal flora integrity while clearing the infection.
Solution Approach 2:
The patent introduces polymeric immunoglobulins as intermediary substances that bind and neutralize C. difficile toxins (Toxin A and Toxin B) in the gastrointestinal tract. These immunoglobulins act as mediators between the host immune system and the pathogen, providing protection without the collateral damage of antibiotics.
4Reliability
If relapse prevention is pursued through repeated antibiotic courses, then infection recurrence is reduced, but treatment complexity and duration increase
Solution Approach 1:
The patent addresses relapse prevention by using polymeric immunoglobulins that provide sustained toxin neutralization without the need for repeated antibiotic courses. The polymeric structure ensures prolonged stability and activity in the gastrointestinal environment, reducing treatment duration and preventing relapses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen-specific secretory IgA and IgM therapeutics effectively bind and neutralize C. difficile toxins, reducing relapse rates and maintaining intestinal flora integrity, offering a more economical and physiologically effective treatment option compared to traditional immunoglobulin therapies.
Implementation Method 1
The antigen-specific secretory IgA and IgM therapeutics effectively bind and neutralize C. difficile toxins
Data Source
AI summary
A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.